308 related articles for article (PubMed ID: 8952536)
21. Molecular analysis of the PML/RAR alpha chimeric gene in pediatric acute promyelocytic leukemia.
Kane JR; Head DR; Balazs L; Hulshof MG; Motroni TA; Raimondi SC; Carroll AJ; Behm FG; Krance RA; Shurtleff SA; Downing JR
Leukemia; 1996 Aug; 10(8):1296-302. PubMed ID: 8709634
[TBL] [Abstract][Full Text] [Related]
22. THAP1 is a nuclear proapoptotic factor that links prostate-apoptosis-response-4 (Par-4) to PML nuclear bodies.
Roussigne M; Cayrol C; Clouaire T; Amalric F; Girard JP
Oncogene; 2003 Apr; 22(16):2432-42. PubMed ID: 12717420
[TBL] [Abstract][Full Text] [Related]
23. Reverse transcription-polymerase chain reaction for PML-RAR alpha fusion transcripts in acute promyelocytic leukemia and its application to minimal residual leukemia detection.
Ikeda K; Sasaki K; Tasaka T; Nagai M; Kawanishi K; Takahara J; Irino S
Leukemia; 1993 Apr; 7(4):544-8. PubMed ID: 8385249
[TBL] [Abstract][Full Text] [Related]
24. PML suppresses oncogenic transformation of NIH/3T3 cells by activated neu.
Liu JH; Mu ZM; Chang KS
J Exp Med; 1995 Jun; 181(6):1965-73. PubMed ID: 7759992
[TBL] [Abstract][Full Text] [Related]
25. The PML growth-suppressor has an altered expression in human oncogenesis.
Koken MH; Linares-Cruz G; Quignon F; Viron A; Chelbi-Alix MK; Sobczak-Thépot J; Juhlin L; Degos L; Calvo F; de Thé H
Oncogene; 1995 Apr; 10(7):1315-24. PubMed ID: 7731682
[TBL] [Abstract][Full Text] [Related]
26. Retinoic acid receptor alpha in acute promyelocytic leukaemia.
de Thé H; Dejean A
Cancer Surv; 1992; 14():195-203. PubMed ID: 1330303
[TBL] [Abstract][Full Text] [Related]
27. The puzzling multiple lives of PML and its role in the genesis of cancer.
Ruggero D; Wang ZG; Pandolfi PP
Bioessays; 2000 Sep; 22(9):827-35. PubMed ID: 10944585
[TBL] [Abstract][Full Text] [Related]
28. The biologic function of PML and its role in acute promyelocytic leukemia.
Mu ZM; Le XF; Glassman AB; Chang KS
Leuk Lymphoma; 1996 Oct; 23(3-4):277-85. PubMed ID: 9031108
[TBL] [Abstract][Full Text] [Related]
29. [Expression of promyelocytic leukaemia protein in lung carcinomas and clinical significance thereof].
Zhao ZL; Huang QY; Xu S; Zhang L; Zhao HR
Zhonghua Yi Xue Za Zhi; 2006 Dec; 86(47):3362-6. PubMed ID: 17313836
[TBL] [Abstract][Full Text] [Related]
30. PML/RAR alpha+ U937 mutant and NB4 cell lines: retinoic acid restores the monocytic differentiation response to vitamin D3.
Testa U; Grignani F; Barberi T; Fagioli M; Masciulli R; Ferrucci PF; Seripa D; Camagna A; Alcalay M; Pelicci PG
Cancer Res; 1994 Aug; 54(16):4508-15. PubMed ID: 7519122
[TBL] [Abstract][Full Text] [Related]
31. Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway.
Yoshida H; Kitamura K; Tanaka K; Omura S; Miyazaki T; Hachiya T; Ohno R; Naoe T
Cancer Res; 1996 Jul; 56(13):2945-8. PubMed ID: 8674046
[TBL] [Abstract][Full Text] [Related]
32. The promyelocytic leukemia nuclear body: sites of activity?
Eskiw CH; Bazett-Jones DP
Biochem Cell Biol; 2002; 80(3):301-10. PubMed ID: 12123283
[TBL] [Abstract][Full Text] [Related]
33. A role for PML and the nuclear body in genomic stability.
Zhong S; Hu P; Ye TZ; Stan R; Ellis NA; Pandolfi PP
Oncogene; 1999 Dec; 18(56):7941-7. PubMed ID: 10637504
[TBL] [Abstract][Full Text] [Related]
34. Cell type- and differentiation stage-dependent expression of PML domains in rat, detected by monoclonal antibody HIS55.
Lam YW; Ammerlaan W; O WS; Kroese F; Opstelten D
Exp Cell Res; 1995 Dec; 221(2):344-56. PubMed ID: 7493633
[TBL] [Abstract][Full Text] [Related]
35. Modulation of CREB binding protein function by the promyelocytic (PML) oncoprotein suggests a role for nuclear bodies in hormone signaling.
Doucas V; Tini M; Egan DA; Evans RM
Proc Natl Acad Sci U S A; 1999 Mar; 96(6):2627-32. PubMed ID: 10077561
[TBL] [Abstract][Full Text] [Related]
36. Induction of the PML protein by interferons in normal and APL cells.
Chelbi-Alix MK; Pelicano L; Quignon F; Koken MH; Venturini L; Stadler M; Pavlovic J; Degos L; de Thé H
Leukemia; 1995 Dec; 9(12):2027-33. PubMed ID: 8609713
[TBL] [Abstract][Full Text] [Related]
37. PML nuclear bodies are general targets for inflammation and cell proliferation.
Terris B; Baldin V; Dubois S; Degott C; Flejou JF; Hénin D; Dejean A
Cancer Res; 1995 Apr; 55(7):1590-7. PubMed ID: 7882370
[TBL] [Abstract][Full Text] [Related]
38. Characterization of the PML-RAR alpha chimeric product of the acute promyelocytic leukemia-specific t(15;17) translocation.
Nervi C; Poindexter EC; Grignani F; Pandolfi PP; Lo Coco F; Avvisati G; Pelicci PG; Jetten AM
Cancer Res; 1992 Jul; 52(13):3687-92. PubMed ID: 1319828
[TBL] [Abstract][Full Text] [Related]
39. The PML/RARalpha fusion protein inhibits tumor necrosis factor-alpha-induced apoptosis in U937 cells and acute promyelocytic leukemia blasts.
Testa U; Grignani F; Samoggia P; Zanetti C; Riccioni R; Lo Coco F; Diverio D; Felli N; Passerini CG; Grell M; Pelicci PG; Peschle C
J Clin Invest; 1998 May; 101(10):2278-89. PubMed ID: 9593784
[TBL] [Abstract][Full Text] [Related]
40. Monoclonal antibodies PG-B6a and PG-B6p recognize, respectively, a highly conserved and a formol-resistant epitope on the human BCL-6 protein amino-terminal region.
Flenghi L; Bigerna B; Fizzotti M; Venturi S; Pasqualucci L; Pileri S; Ye BH; Gambacorta M; Pacini R; Baroni CD; Pescarmona E; Anagnostopoulos I; Stein H; Asdrubali G; Martelli MF; Pelicci PG; Dalla-Favera R; Falini B
Am J Pathol; 1996 May; 148(5):1543-55. PubMed ID: 8623923
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
